NeoStem is developing an immunotherapeutic applicable across multiple solid tumors with Special Protocol Assessment, Fast Track and Orphan Drug designations for a Phase 3 program in metastatic melanoma and near-term development milestones.
Enhancingthe body’s healing response
Rebalancingthe immune system
Innovatingdevelopment and manufacturing of cell-based therapies
NeoStem’s subsidiary, PCT, provides development manufacturing capabilities to the cell therapy industry while supporting the development of NeoStem’s proprietary cell therapy products.
NeoStem’s Investigational Targeted Cancer Immunotherapy For Late Stage Melanoma (2 minute)
See how NeoStem's Phase III investigational targeted cancer immunotherapy, NBS20 (eltrapuldencel-T), is created and administered. The product candidate is being evaluated for the treatment of patients suffering from late stage malignant melanoma.
News + EventsNeoStem, Inc. Announces 2014 Year-End Financial Results and Provides Corporate Update March 2, 2015 - Learn MoreNeoStem Announces Addition of Experienced Scientist and Biotechnology Executive Peter G. Traber, MD, to Its Board of Directors January 22, 2015 - Learn MoreNeoStem Receives Drug Manufacture License for Irvine Facility January 20, 2014 - Learn More
After an extensive search, it is with great pleasure that I have the opportunity today to introduce Dr. Dav.... Read More
We are particularly encouraged by the results of our PreSERVE AMI trial both from our own reading of the in.... Read More